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Temporal Trends in Long-Term Survival and Cure Rates in
Esophageal Cancer
A SEER Database Analysis
Attila Dubecz, MD,* Isabell Gall, MD,* Norbert Solymosi, DVM, PhD,† Michael Schweigert, MD,*
Jeffrey H. Peters, MD,‡ Marcus Feith, MD,§ and Hubert J. Stein, MD*
Purpose: To assess long-term temporal trends in population-based
survival and cure rates in patients with esophageal cancer and
compare them over the last 3 decades in the United States.
Methods: We identified 62,523 patients with cancer of the esoph-
agus and the gastric cardia diagnosed between 1973 and 2007 from
the Surveillance, Epidemiology, and End Results database. Long-
term cancer-related survival and cure rates were calculated. Stage-
by-stage disease-related survival curves of patients diagnosed in
different decades were compared. Influence of available variables on
survival and cure was analyzed with logistic regression.
Results: Ten-year survival was 14% in all patients. Disease-related
survival of esophageal cancer improved significantly since 1973.
Median survival in Surveillance, Epidemiology, and End Results
stages in local, regional, and metastatic cancers improved from 11,
10, and 4 months in the 1970s to 35, 15, and 6 months after 2000.
Early stage, age 45 to 65 years at diagnosis and undergoing surgical
therapy were independent predictors of 10-year survival. Cure rate
improved in all stages during the study period and were 73%, 37%,
12%, and 2% in stages 0, 1, 2, and 4, respectively, after the year
2000. Percentage of patients undergoing surgery improved from
55% in the 1970s to 64% between 2000 and 2007. Proportion of
patients diagnosed with in situ and local cancer remains below 30%.
Conclusion: Long-term survival with esophageal cancer is poor but
survival of local esophageal cancer improved dramatically over the
decades. Complete cure of nonmetastatic esophageal cancer seems
possible in a growing number of patients. Early diagnosis and
treatment are crucial.
Key Words: Esophageal cancer, Temporal trends, Long-term sur-
vival, Cure.
(J Thorac Oncol. 2012;7: 443–447)
In the past 30 years, improvement in preoperative diagnos-tics, surgical techniques, intensive therapy, and adjuvant
chemoradiation enabled expert centers to achieve excellent
results in operative mortality and 5-year survival, introducing
the term “cure” among goals of esophageal cancer treatment.1
Nevertheless, little is known if these patients are really cured
of their malignant disease, or the reported, admittedly im-
proved survival rates are just consequences of an institutional
selection bias, changing epidemiology of esophageal carci-
noma, or in cases of early cancer, products of lead time bias
and a short follow-up.2–4 To minimize these biases and assess
national temporal trends in long-term survival and possible
cure rates in patients with carcinoma of the esophagus and the
gastric cardia, we analyzed Surveillance, Epidemiology, and
End Results (SEER) cancer registry data, comparing cancer-
related survival in each stage through the last 3 decades in the
United States.
METHODS
SEER Program
The SEER program of the National Cancer Institute is
the only comprehensive source of population-based cancer
information in the United States. SEER currently collects and
publishes incidence, treatment information, and survival data
from population-based cancer registries covering more than
28% of the U.S. population. It collects data within the defined
geographic regions of its registries, primarily from medical
records within hospitals, outpatient surgical, pathology, and
radiology centers. The routine data collection includes de-
tailed information on demographics, diagnosis, and tumor
characteristics. The registries maintain active follow-up of all
cases.5
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Study Population
The SEER database was queried for all cases of pri-
mary carcinoma of the esophagus and the gastric cardia using
tumor site codes C15.0 to 15.5, 15.8, 15.9, and 16.0 diag-
nosed between 1973 and 2007. Both adenocarcinoma and
squamous cell cancers were included in the search. We
limited our analysis to patients with known SEER Stage
information (Table 1). From this group, we excluded all
patients who were diagnosed at autopsy or from death cer-
tificate data. The final study cohort comprised 62,563 patients
with cancer of the esophagus and the gastric cardia. Informa-
tion about age at diagnosis, sex, race, tumor stage and
histology, tumor location, and cancer therapy was obtained
from SEER. Patients were grouped based on histology into
categories of adenocarcinoma, squamous cell carcinoma, and
“other” histological types. Tumors were dichotomized ac-
cording to their location to distal (SEER tumor site codes
C15.2: abdominal esophagus, C15.5: lower thoracic portion,
and between 32 and 40 cm and C16.0: cardia) and nondistal
tumors.
Definition of (Population) Cure
Population or statistical cure occurs when the mortality
rate associated with the disease returns to the same level as
that expected in the general population. Equivalently, the
relative survival curve is seen to reach a plateau, the proba-
bility of surviving an additional year nears 100%.
Statistical Analysis
We estimated the prevalence with 95% confidence
intervals of the 10-year survival rate among patients with
esophageal cancer by stage at diagnosis. Univariate analysis
was performed by Pearson’s 2 test to determine the relation-
ship between predictor variables (age, gender, race and mar-
ital status, and decade of diagnosis) and primary outcome
(10-year survival). Multivariate logistic regression was used
to model the relationship of 10-year survival and independent
predictors. The method of Kaplan-Meier was used to assess
and compare disease-related survival of patients with various
variables. Survival curves were compared by log-rank anal-
ysis. For estimation of cure fractions proportional hazard cure
model was used.6 All analyses were conducted using R 2.13.0
(R Development Core Team [2011]. R: A language and
environment for statistical computing. R Foundation for Sta-
tistical Computing, Vienna, Austria. ISBN 3–900051-07–0,
URL http://www.R-project.org/).
RESULTS
A total of 62,563 patients diagnosed with primary
esophageal cancer between 1973 and 2007 with known SEER
Stage status were identified from the SEER registry (Table
2.). Most patients were male (76–78%) and white (74–86%).
Patients with cancer of the esophagus and the gastric cardia
were significantly older after 2000 than in the 1970s. Histol-
ogy changed markedly during the study period, proportion of
adenocarcinoma almost doubled from 35% in the 1970s to
61% after the year 2000. Proportion of distal cancer remained
around 40% throughout the study period. Median survival of
patients with SEER stage 0 (in situ—Table 1) cancer was 5
years in the 1970s and is not yet reached in patients diagnosed
with in situ carcinoma after 1980 (Table 3.). In patients
diagnosed with SEER stage 1 (local) cancer, median survival
improved from 11 months in the 1970s to 35 months after the
year 2000. In patients with SEER stage 2 (regional) cancer,
median survival improved 50% through the last 30 years to
15 months. Median survival of patients with metastatic
(SEER stage 4) cancer of the esophagus and the gastric cardia
improved slightly from 4 to 6 months from 1973 to 2007. The
Kaplan-Meier survival curves (Figure 1A–E) of all patients
and stratified by SEER stage show a consistent and statisti-
cally significant improvement in cancer-related survival in all
patients and in patients with local, regional, and metastatic
cancer of the esophagus and the gastric cardia from the 1970s
to 2007. There is no statistically significant difference be-
tween survival curves in patients with in situ disease, prob-
ably because of the low number of cases in the first half of the
study period.
In the 1970s, no more than 5% of all patients were
cured of esophageal cancer, but this proportion grew to 18%
after the year 2000 (Table 4). Almost 75% of all patients
diagnosed with in situ cancer of the esophagus and the gastric
cardia are cured today, compared with 19% 30 years ago.
TABLE 1. Definition of SEER Stages
Stage Definition
0—In situ A noninvasive neoplasm
1—Local An invasive neoplasm confined entirely to the
organ of origin
2—Regional Extended (1) directly into surrounding organs
and (2) into regional lymph nodes
4—Metastatic Has metastasized to distant organs
SEER, Surveillance, Epidemiology, and End Results.
TABLE 2. Demographical Characteristics of the
Study Population
Variable 1970s 1980s 1990s 2000s p
n 4,251 9,153 16,390 32,769
Median age (yr) 63 65 67 68 0.001
Men (%) 76 75 77 78 0.001
White (%) 74 78 81 86 0.001
Adenocarcinoma (%) 35 45 53 61 0.001
Distal cancer (%) 40 43 41 37 0.001
5-year survival (%) 9 13 18 22 0.001
TABLE 3. Median Survival (in Months) of Patients with
Different Stages of Carcinoma of the Esophagus and the
Gastric Cardia According to Time of Diagnosis
SEER Stage In Situ Local Regional Metastatic
1970s 60 11 10 4
1980s NA 18 11 5
1990s NA 24 13 5
2000s NA 35 15 6
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Chance of cure falls sharply in invasive disease (SEER stage
1): only 37% of patients are cured even after 2000, but it is a
clear improvement from 9% in the 1970s. Cure rate of
patients with regionally advanced cancer improved from 4 to
12% during the study period. Only 2% of patients with
metastatic cancer of the esophagus or the gastric cardia
experienced cure.
Table 5 shows the rate of surgical therapy relative to the
time of diagnosis. Patients today have a significantly greater
chance of undergoing surgical treatment than before. Percent-
age of patients undergoing radiation therapy remained around
50% throughout the study period.
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FIGURE 1. A, Kaplan-Meier survival curves of all Surveillance, Epidemiology, and End Results (SEER) patients with cancer of
the esophagus and the gastric cardia according to the time of diagnosis. B, Kaplan-Meier survival curves of patients with local
esophageal cancer according to the time of diagnosis. C, Kaplan-Meier survival curves of patients with regional esophageal
cancer according to the time of diagnosis. D, Kaplan-Meier survival curves of patients with metastatic esophageal cancer ac-
cording to the time of diagnosis. E, Kaplan-Meier survival curves of patients with in situ esophageal cancer according to time
of diagnosis.
TABLE 4. Percentage of Cured Patients with Esophageal
Cancer Through the Decades
Stages In Situ Local Regional Metastatic All
1970s 19 9 4 0.6 5
1980s 50 18 6 0.8 8
1990s 63 26 10 1 13
2000s 73 37 12 2 18
TABLE 5. Changes of Treatment Patterns in Patients with
Cancer of the Esophagus and the Gastric Cardia
1970s 1980s 1990s 2000s p
No surgical treatment (%) 45 51 43 36 0.001
Radiation therapy (%) 47 47 51 52 0.001
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Changes in distribution of patients according to stage at
diagnosis are shown in Table 6. Largest relative increase
since the 1970s occurred in patients with in situ cancer, but
patients diagnosed in this stage still make up only 2% of all
cases. Proportion of patients with metastatic cancer at diag-
nosis is the largest in the last decade of the study period with
37%. Table 7 shows the results of multivariate logistic re-
gression of the factors associated with long-term survival in
SEER patients with cancer of the esophagus and the gastric
cardia. Patients 65 years, particularly those 80 years,
women, and patients not undergoing surgical treatment, were
associated with decreased odds for 5-year survival. The same
variables, except female sex, were associated with decreased
probability for 10-year survival.
DISCUSSION
Our analysis of population-based data shows that long-
term survival with esophageal cancer is rare. Only 14% of
patients survive 10 years after diagnosis. Fortunately, 5- and
10-year survival rates show a substantial improvement since
the 1970s, but according to several authors, these numbers
could be tainted by a lead-time bias caused by the recent
increase of early diagnoses.2–4,7,8 According to our results
though, this might not be true in cancer of the esophagus and
the gastric cardia. Despite a 400% increase in the proportion
of patients diagnosed with in situ cancer between 1973 and
2008, the combined SEER stages 0 and 1 (in situ and local
cancers) still make up only 30% of all diagnosed cases today,
the same rate as 30 years ago. Furthermore, the proportion of
metastasized patients is at an all-time high since 1973, prob-
ably due to stage migration caused by improvements in
preoperative diagnostic staging.
Analysis of the long-term survival of patients with in
situ cancer shows that reporting 5-year survival rates are
insufficient to describe the fate of these patients because
cancer-related deaths occur even 25 to 30 years after the
initial diagnosis. Furthermore, more than 60% of patients
who did not undergo any treatment will live at least 5 years
after diagnosis. Median survival of patients with local cancer
has improved dramatically from 11 months in the 1970s to 35
months in this decade. Disease-related survival of regional
and metastatic esophageal cancer has improved significantly
but to a lesser extent during this time period.
Cure is the word that all cancer patients, journalist, and
policymakers would like to hear, but physicians are often
reluctant to use.9 In our study population, cancer-related
deaths occur even 25 to 30 years after diagnosis of in situ or
local disease, but because there is a certain percentage of the
patient population in each stage who experience long-term
survival and do not die of esophageal cancer, we can postu-
late that these patients are probably “cured” from their ma-
lignant disease. Furthermore, this proportion is markedly
increasing over the last 3 decades. Our results show that 73%
of all patients with in situ carcinoma of the esophagus and the
gastric cardia can be cured today. In addition, there is a 12 to
37% chance, even in patients with locoregional, invasive
disease for a long-term survival with complete cure. The
diagnosis of metastatic cancer of the esophagus or the gastric
cardia means the same in the 21st century as 30 years ago:
most patients experience a very short survival and minimal
chance of cure. One could argue that our data of improved
stage-specific survival and cure rates are confounded by the
effect of stage migration, but our all-stage analysis (Figure
1A) shows similar improvements.
The driving forces behind these changes in long-term
survival in patients with esophageal cancer are unclear.
Changes in tumor biology and epidemiology, better access to
up-to-date medical care, and advancements in surgical and
adjuvant therapy could all have an influence.10 According to
our data, patients younger than 65 years, with early stage
cancer, and patients receiving surgical therapy have the
highest chance for long-term survival. Although the propor-
tion of patients with adenocarcinoma doubled during the
study period, type of histology does not seem to influence
long-term survival. Additionally, long-term survival of
TABLE 6. Percentage of Patients’ Stage at Diagnosis
According to Time of Diagnosis
Stage In Situ (%) Local (%) Regional (%) Metastatic (%)
1970s 0.4 29 37 34
1980s 1 26 37 36
1990s 1.6 30 35 33
2000s 2 27 34 37
TABLE 7. Predictors of 10-Year Survival in Patients with
Esophageal Cancer by Multivariate Analysis
10 yr 5 yr
 OR p  OR p
Male
Female 0.14 1.16 0.474 0.18 1.20 0.028
Adeno
Other 0.48 0.62 0.117 0.00 1.00 0.980
SCC 0.04 0.96 0.877 0.27 0.76 0.009
Race other
White 0.03 1.03 0.916 0.02 1.02 0.845
Stage 0
1 2.20 0.11 0.000 1.56 0.21 0.000
2 3.44 0.03 0.000 2.61 0.07 0.000
4 4.82 0.01 0.000 3.95 0.02 0.000
C15.2C15.5C16.0
Others 0.41 0.66 0.082 0.00 1.00 0.984
Age 45–65 (yr)
45 0.10 0.90 0.812 0.15 1.16 0.395
65–80 0.44 0.64 0.013 0.19 0.83 0.014
80 2.28 0.10 0.002 0.86 0.42 0.000
Surgery no
Yes 1.81 6.10 0.000 1.33 3.77 0.000
1970s
1980s 0.43 1.53 0.096 0.62 1.86 0.000
1990s 0.06 0.95 0.830 0.70 2.01 0.000
2000s 16.70 0.00 0.955 0.87 0.42 0.000
OR, odds ratio.
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esophageal cancer improved despite the continuously increas-
ing median age of patients in each decade.
Based on our data, access to adequate medical care of
patients with esophageal cancer has improved in the United
States since 1973 because surgery rates improved markedly
from 55% in the 1970s to 64% after 2000. Utilization of
radiation therapy remained approximately the same during
the study period.
Medical advances are probably affecting the temporal
changes in long-term survival in patients with esophageal
cancer, but the exact amount of their influence is difficult to
measure. Quality of surgical and perioperative therapy has
obviously improved in the last 30 years, but superior 30-day
postoperative mortality rates do not necessarily translate to
better long-term outcomes. In their landmark article, Earlam
and Cunha-Melo11 reviewed results of esophageal cancer
therapy from the 1950s to 1979 and found operative mortality
rates of 26 and 33% (eastern and western results, respec-
tively). These rates improved from 7 to 19% between 1980
and 1988 reported by Muller et al.,12 and from 5.2 to 8.9%
between 1990 and 2000 according to the literature review
published by Jamieson et al.13 Comparison of long-term
survival rates based on these reviews of retrospective single-
center experiences with several inherent biases is almost
impossible.
Obviously, our study has several limitations. First,
there is always the possibility of misclassification of cancer
stage and vital status when using administrative claims data.
Additionally, calculating cause-specific survival requires ac-
curate classification of cause-of-death, but the definition of
cancer-related death is somewhat arbitrary producing results
that must be interpreted with caution. For example, our
results of a 2% cure-rate in metastatic esophageal cancer are
most likely overestimated based on everyday clinical experi-
ence. Second, there is no information in the SEER database
regarding patient comorbidities or chemotherapy. Despite the
limited dataset though, the SEER database has several advan-
tages which ensure a very high accuracy of data: population-
based case identification with detailed review of medical and
pathology records, rigorous data collection and quality con-
trol standards, and a patient follow-up rate of greater than
97%. These data were thoroughly audited for accuracy and
completeness; the main limitation of SEER data is not valid-
ity but rather extent of clinical information. Furthermore,
comparison studies have found that major surgery and radi-
ation are accurately recorded in the SEER data.14–19 Thus, it
can be reasonably assumed that our data on patient charac-
teristics, tumor pathology and staging, treatment modalities,
and survival status are fairly accurate, and even with some-
what limited data, our conclusions are probably justified.
CONCLUSIONS
Based on our analysis of the SEER database, we can
conclude that complete cure of nonmetastatic esophageal
cancer seems possible in a growing number of patients, but
early diagnosis and treatment is crucial. The significant im-
provements in the long-term survival of locoregional cancer
over the last 3 decades are not caused by lead time alone,
advancements in surgical and perioperative therapy, and
access to adequate treatment accumulate in these changes, but
there is still a significant room for further progress.
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